FindTrial
Sign In

Nadunolimab

DRUG4 trials

Sponsors

Cantargia AB, M.D. Anderson Cancer Center, Dan Feng, Robert Samstein

Conditions

Acute Myelogenous Leukemia (AML)High-risk Lung NodulesMetastatic Microsatellite Stable Colorectal CarcinomaMyelodysplastic Syndrome(MDS)Triple Negative Breast Cancer

Phase 1

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
CompletedNCT05181462
Cantargia ABTriple Negative Breast Cancer
Start: 2022-01-11End: 2026-05-08Updated: 2026-05-27
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
RecruitingNCT06548230
M.D. Anderson Cancer CenterAcute Myelogenous Leukemia (AML), Myelodysplastic Syndrome(MDS)
Start: 2025-03-05End: 2029-12-01Target: 40Updated: 2026-03-09
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
RecruitingNCT07281716
Dan FengMetastatic Microsatellite Stable Colorectal Carcinoma
Start: 2025-12-01End: 2028-12-15Target: 24Updated: 2026-02-19

Phase 2

Immunoprevention for High-risk Lung Lesions
RecruitingNCT07284485
Robert SamsteinHigh-risk Lung Nodules
Start: 2026-05-21End: 2029-12-17Target: 59Updated: 2026-06-08

Related Papers

Abstract CT082: A phase 1b/2 study of toripalimab and nadunolimab for the treatment of chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC)
Cancer Research2026-04-17
Abstract P1-09-29: Safety, efficacy and emerging biomarker data from the Phase Ib part of a Phase Ib/II clinical study of nadunolimab in combination with gemcitabine and carboplatin in patients with advanced triple negative breast cancer (TRIFOUR study)
Clinical Cancer Research2025-06-13
Abstract 6429: A surrogate to the anti-IL1RAP antibody nadunolimab induces tumor microenvironment changes to the metastatic lung and reduces metastatic lesions in mouse models of metastatic cancer
Cancer Research2023-04-04